Veracyte Named a San Francisco Bay Area "Top Workplace" For Fourth Consecutive Year

Monday, June 26, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

SOUTH SAN FRANCISCO, Calif., June 26, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) announced today

that it has been awarded a 2017 Top Workplaces honor by the Bay Area News Group. This marks the fourth consecutive year that Veracyte has received this prestigious award, which is based solely on the results of an annual survey of Bay Area-company employees.


are honored and humbled to receive this award and grateful to our employees for their strong enthusiasm and support for Veracyte," said Bonnie Anderson, Veracyte's chairman and chief executive officer. "We are passionate about improving patient care with our genomic tests and believe we have built a culture that reflects this passion, which is key to fueling our continued success."

The Top Workplaces award winners are determined by results of an employee feedback survey administered by WorkplaceDynamics, LLC, a leading research firm that specializes in organizational health and workplace improvement. Several key aspects of workplace culture were measured for the award, including organizational alignment, effective execution and meaningful connection with employees.

The Bay Area News Group published the complete list of 2017 Top Workplaces on Sunday, June 25. The list of winners is available at the Bay Area News Group website.

Veracyte's corporate and industry leadership has been recognized consistently over the past several years. In 2016, the company received the prestigious Edison Award honoring excellence in new product and service development, marketing, human-centered design and innovation. Ms. Anderson has also been named to Fast Company's 2015 list of the "100 Most Creative People in Business" and was named by the San Francisco Business Times in 2015 as one of the "Bay Area's Most Admired CEOs."

About Veracyte Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit and follow the company on Twitter (@Veracyte).

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.


To view the original version on PR Newswire, visit:

SOURCE Veracyte

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store